Featured

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

North America Session – From reaction to result: Connecting chemistry and biology for smarter drug discovery

A molecule passes through many hands in drug discovery. Medicinal chemists design and synthesise it, analytical scientists characterise it, and biology teams evaluate its activity. Yet the scientific knowledge generated along the way often remains fragmented across disconnected systems, making it difficult to connect what was made, how it was… Read More

Webinar date:
Supported by Benchling
#Featured Webinars #Webinars

#Artificial intelligence (AI) #Automation #Benchling #Drug discovery #Webinar

Europe Session – From reaction to result: Connecting chemistry and biology for smarter drug discovery

A molecule passes through many hands in drug discovery. Medicinal chemists design and synthesise it, analytical scientists characterise it, and biology teams evaluate its activity. Yet the scientific knowledge generated along the way often remains fragmented across disconnected systems, making it difficult to connect what was made, how it was… Read More

Webinar date:
Supported by Benchling
#Featured Webinars #Webinars

#Biomarkers #Drug discovery #Evotec #Immunoassays #Webinar

Measuring what matters: Applying ultrasensitive immunoassays for clinical biomarkers

When biomarkers are present at very low concentrations, conventional immunoassays may not provide the sensitivity needed to generate reliable, meaningful data. This can limit the ability to assess target engagement, monitor pharmacodynamic responses and track biomarker changes during treatment. Ultrasensitive immunoassays offer new opportunities to address these challenges. In this… Read More

Webinar date:
Supported by Evotec
#Featured Webinars #Webinars

#Crown Bioscience #Drug discovery #PDX models #Webinar

Beyond the model: Exploring warm PDX benefits and onsite expertise

Patient-derived xenograft (PDX) models are a valuable tool in oncology research, helping researchers evaluate therapeutic efficacy in preclinical settings using models that retain key characteristics of human tumours. In this webinar, Crown Bioscience will highlight the capabilities of its PDX model portfolio, with a particular focus on the benefits of… Read More

Webinar date:
Supported by Crown Bioscience
#Featured Webinars #Webinars

#Biomarkers #Drug discovery #Evotec #Webinar

From PK/PD and Biomarkers to decision-making: How modeling shapes clinical strategy

Clinical trials continue to experience high attrition rates, with lack of efficacy being one of the leading causes of failure. However, in many cases, these failures do not reflect a lack of drug efficacy, but rather limitations in translational biomarker strategies and selection of disease-relevant pharmacodynamic (PD) biomarkers, suboptimal dose… Read More

Webinar date:
Supported by Evotec
#Featured Webinars #Webinars

Cell and gene therapy
#Cell and gene therapy #Cell therapy #Drug development #Drug discovery #Gene therapy

Advances and challenges in cell and gene therapies

Hosted by Drug Discovery World and supported by Bio-Techne, this webinar explores the advances and challenges taking place within the cell and gene therapy field. Hear from Hans Schambye CEO at BOOST Pharma, Lucas Arruda, CSO at CuraCell, and Brandon Cieniewicz, Director, Research & Development at CERo Therapeutics. Throughout the… Read More

Webinar date:
Sponsored by Bio-Techne
#Featured Webinars

Webinars

#Automated workflows #Automation #Drug discovery #Orchestration #Thermo Fisher Scientific #Webinar

The orchestrated lab: Moving beyond siloed automation

Many laboratories have invested in automation, yet workflows often remain fragmented, with disconnected instruments, data, and processes creating inefficiencies and limiting scalability. As scientific workflows grow more complex, automation alone is no longer enough. Leading labs are now embracing orchestration, the coordination of instruments, robotics, software, data, and people across the… Read More

Webinar date:
Supported by Thermo Fisher Scientific
#Webinars

#Drug discovery #Fragment-based drug discovery #Hit to lead #Webinar

Accelerating hit discovery for hard-to-target proteins: A fragment library approach applied to MyD88

Fragment-based drug discovery (FBDD) offers an efficient route to explore chemical space, but critical bottlenecks remain. Commercial fragment libraries are either too large to screen routinely with biophysical methods or too small to capture sufficient chemical diversity for challenging targets. Moreover, fragment expansions into focused compound collections lacks streamlined, integrated… Read More

Webinar date:
Supported by BioDuro and ChemPass
#Webinars

#Champions Oncology #Drug discovery #KRAS #Oncology #Patient-derived tumour models #Tumour models #Webinar

Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived Tumour Models

KRAS mutations are among the most prevalent oncogenic drivers in solid tumours, yet predicting which patients will respond to targeted therapy — and understanding why resistance inevitably emerges — remains one of the central challenges in oncology drug development. ‘Cracking KRAS: Decoding Sensitivity and Resistance to Pan-RAS(ON) Inhibition Across Patient-Derived… Read More

Webinar date:
Supported by Champions Oncology
#Webinars

#Biosafety testing #Drug discovery #Next generation sequencing #Webinar

How ViruSure implemented an NGS-based AVA assay with enhanced sensitivity and specificity

Biopharmaceutical manufacturers are under increasing pressure to deliver safe, reliable products at speed – yet adventitious viral agent (AVA) testing remains one of the most significant bottlenecks in the quality control process. Traditional AVA workflows require numerous parallel and sequential assays, often taking weeks to complete and contributing… Read More

Webinar date:
Supported by Oxford Nanopore Technologies and ViruSure
#Webinars

Antibody discovery concept
#Artificial intelligence (AI) #Biologics #Drug discovery #Therapeutic Antibodies #Webinar

Introducing Benchling Biologics: AI infrastructure for modern drug discovery

Antibody discovery is being reshaped by two forces: an explosion of novel formats and the growing role of AI across the DBTL loop. But most teams are still running antibody programmes on software that hasn’t kept pace with science, leaving data siloed and relationships missing. In this webinar on 11… Read More

Webinar date:
Supported by Benchling
#Webinars

#Drug discovery #Surface plasmon resonance #Webinar

Scale your drug discovery programme by 12x: Introducing the world’s first 48-Channel SPR platform

Surface plasmon resonance (SPR) has long been the gold standard for characterising molecular interactions in drug discovery, but throughput limitations have historically constrained its use in early-stage screening campaigns where large numbers of compounds or biologics candidates require rapid triage. The Carterra Vega changes that equation.  This… Read More

Webinar date:
Supported by Carterra
#Webinars

Peptides
#Artificial intelligence (AI) #Drug discovery #Peptides #Webinar

The art and science of cyclic peptide drug design: From experimental discovery to AI-driven computation

Cyclic peptides have a special power in the therapeutic space — they’re larger and more specific than small molecules, and more permeable and cost-effective than antibodies. These qualities enable them to conquer two of the biggest challenges in modern drug development: prosecuting flat intracellular protein-protein interactions (PPIs) and achieving oral… Read More

Webinar date:
Supported by BioDuro
#Webinars

Antibody-drug conjugates
#Antibody drug conjugate (ADC) #Drug discovery #Webinar

Accelerating ADC discovery through strategically integrated chemistry, biology, and DMPK

Antibody-drug conjugates (ADCs) hold great promise in targeted therapies, yet their development in the drug discovery phase involves complex challenges in chemistry, biology, and DMPK. This webinar demonstrates how integrated strategies help overcome these hurdles and support informed preclinical decisions. Innovative chemistry enables efficient conjugation, optimised linkers, and payload selection,… Read More

Webinar date:
Supported by BioDuro
#Webinars

#Antibody drug conjugate (ADC) #LC-MS #Monoclonal antibodies #Oligonucleotides #Webinar

Advanced LC-MS bioanalytical strategies for biologics: mAbs, ADCs, and oligonucleotides in complex biological matrices

This event, hosted by DDW and supported by Evotec, will explore cutting-edge LC-MS-based bioanalytical approaches tailored for the quantitative analysis of therapeutic proteins, such as monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), fusion protein biomarkers, and oligonucleotides in biological fluids and tissues. The webinar will feature a presentation by Dr Marco… Read More

Webinar date:
Supported by Evotec
#Webinars

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

From plasma to prediction: Mapping disease trajectories with proteomics at unprecedented scale

What if you could see disease coming years before symptoms appear? Chronos makes that vision a reality. Built on 100 million plasma samples from six million US donors, the platform combines real-world clinical data with high-resolution proteomics to chart molecular changes across time and populations. In this… Read More

Webinar date:
Supported by Standard BioTools
#Webinars

Proteomics
#Drug discovery #Mass spectrometry / NMR #Protein chemistry / Proteomics #Webinar

MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases

Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. This webinar, hosted by DDW and supported by Evotec, will cover a diverse set of applications to illustrate how tailored and targeted proteomics fulfils scientific – and even regulatory –… Read More

Webinar date:
Supported by Evotec
#Webinars

Lab equipment
#Drug discovery #High throughput screening #Protein chemistry / Proteomics #Webinar

Advancing protein analysis with high-throughput multiplexed fluorescence westerns

In this webinar, hosted by DDW, Bio-Techne unveils the next evolution of the Leo System, expanding the capabilities of Simple Western Technology for high-throughput protein analysis. The Leo System now supports integrated dual fluorescence channels—Near-Infrared (NIR) and Infrared (IR)—alongside chemiluminescence, enabling simultaneous detection of multiple targets within 96 samples in… Read More

Webinar date:
Supported by Bio-Techne
#Webinars

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Drug discovery #Webinar

The 2026 Biotech AI Report: Breakthroughs, bottlenecks, and the power shift shaping biotech’s AI future

This webinar, sponsored by Benchling, provides an exclusive readout of what biotech leaders need to know heading into 2026 — and how 100 AI frontrunners are translating AI into real scientific impact. Get a rare, upfront look at what the most advanced biotech teams are actually… Read More

Webinar date:
Supported by Benchling
#Webinars

Metabolomics
#Autoimmune disease #Drug discovery #Lipidomics #Metabolomics #Webinar

Unbiased exploration of biological systems: Leveraging untargeted metabolomics and lipidomics for drug discovery

This webinar, hosted by DDW and supported by Evotec, introduces untargeted metabolomics and lipidomics analyses, which are designed to accelerate research in complex biological systems. The webinar will begin with an overview of the principles behind untargeted approaches, highlighting their importance in capturing a comprehensive molecular snapshot without prior assumptions. Read More

Webinar date:
Supported by Evotec
#Webinars

T cells
#CAR-T #Cell therapy #Drug discovery #Webinar

Technology & techniques to advance your T cell therapy

Accelerate your CAR-T research. Discover high-throughput imaging innovations for assessing cytotoxicity, T cell activation, and proliferation across 2D/3D models. Get proven methods and actionable insights to optimise constructs and scale up your translational assays. You will learn: Ways to evaluate immune cell behavior and function Practical strategies for optimising your… Read More

Webinar date:
Brought to you by Agilent
#Webinars